- Home
- UPXI vs OLMA Comparison
UPXI vs OLMA Comparison
Compare UPXI & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- OLMA
- Stock Information
- Founded
- UPXI 2018
- OLMA 2006
- Country
- UPXI United States
- OLMA United States
- Employees
- UPXI N/A
- OLMA N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- OLMA Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- OLMA Health Care
- Exchange
- UPXI Nasdaq
- OLMA Nasdaq
- Market Cap
- UPXI 339.4M
- OLMA 299.7M
- IPO Year
- UPXI 2021
- OLMA 2020
- Fundamental
- Price
- UPXI $5.25
- OLMA $5.10
- Analyst Decision
- UPXI
- OLMA Strong Buy
- Analyst Count
- UPXI 0
- OLMA 4
- Target Price
- UPXI N/A
- OLMA $24.50
- AVG Volume (30 Days)
- UPXI 12.9M
- OLMA 426.7K
- Earning Date
- UPXI 05-16-2025
- OLMA 08-12-2025
- Dividend Yield
- UPXI N/A
- OLMA N/A
- EPS Growth
- UPXI N/A
- OLMA N/A
- EPS
- UPXI N/A
- OLMA N/A
- Revenue
- UPXI $16,562,327.00
- OLMA N/A
- Revenue This Year
- UPXI $299.03
- OLMA N/A
- Revenue Next Year
- UPXI N/A
- OLMA N/A
- P/E Ratio
- UPXI N/A
- OLMA N/A
- Revenue Growth
- UPXI 1378.83
- OLMA N/A
- 52 Week Low
- UPXI $1.90
- OLMA $2.86
- 52 Week High
- UPXI $22.57
- OLMA $14.41
- Technical
- Relative Strength Index (RSI)
- UPXI 44.64
- OLMA 66.72
- Support Level
- UPXI $4.31
- OLMA $4.97
- Resistance Level
- UPXI $6.50
- OLMA $5.36
- Average True Range (ATR)
- UPXI 1.07
- OLMA 0.30
- MACD
- UPXI -0.05
- OLMA 0.08
- Stochastic Oscillator
- UPXI 15.21
- OLMA 77.82
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products with diversification into the cryptocurrency space via a Solana treasury strategy.
About OLMA Olema Pharmaceuticals Inc.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.